U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H8F2N4O
Molecular Weight 238.1935
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RUFINAMIDE

SMILES

NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1

InChI

InChIKey=POGQSBRIGCQNEG-UHFFFAOYSA-N
InChI=1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)

HIDE SMILES / InChI
Molecular Formula C10H8F2N4O
Molecular Weight 238.1935
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/banzel-drug.htm https://www.drugs.com/mtm/rufinamide.html

Rufinamide is an anti-epileptic drug that is FDA approved for the treatment of lennox-gastaut syndrome (LGS). The principal mechanism of action of rufinamide is modulation of the activity of sodium channels and, in particular, prolongation of the inactive state of the channel. Hormonal contraceptives may be less effective with rufinamide. Patients on valproate should begin at a rufinamide dose lower than 10 mg/kg per day (pediatric patients) or 400 mg per day (adults). Common adverse reactions include headache, dizziness, fatigue, somnolence, and nausea.

CNS Activity

Originator

Approval Year

2008
174
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Modulator
846
 3.8 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
BANZEL

Approved Use

I NDICATIONS AND USAGE BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults. BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults (1)

Launch Date

2008
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.8 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/18503564/
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RUFINAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
70.3 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/18503564/
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RUFINAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.2 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/18503564/
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RUFINAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
10 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204988Orig1s000lbl.pdf
200 mg 2 times / day unknown, oral
dose: 200 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
RUFINAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
66%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204988Orig1s000lbl.pdf
200 mg 2 times / day unknown, oral
dose: 200 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
RUFINAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3600 mg 2 times / day multiple, oral
MTD
Dose: 3600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 3600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503564
healthy
Health Status: healthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503564
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503564
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Other AEs: Depression worsened, Suicidal behavior...
Other AEs:
Depression worsened
Suicidal behavior (serious)
Leukopenia (serious)
Mood change
Central nervous system disorder NOS
Hypersensitivity reaction
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Disc. AE: Fatigue...
Other AEs: QT shortened...
AEs leading to
discontinuation/dose reduction:
Fatigue (1-2)
Other AEs:
QT shortened (serious)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Disc. AE: Convulsion, Rash...
AEs leading to
discontinuation/dose reduction:
Convulsion (2%)
Rash (2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Disc. AE: Vomiting, Dizziness...
AEs leading to
discontinuation/dose reduction:
Vomiting (1%)
Dizziness (3%)
Headache (2%)
Nausea (1%)
Ataxia (1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Central nervous system disorder NOS
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Depression worsened
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Hypersensitivity reaction
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Mood change
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Leukopenia serious
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Suicidal behavior serious
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Fatigue 1-2
Disc. AE
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
QT shortened serious
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Convulsion 2%
Disc. AE
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Rash 2%
Disc. AE
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Ataxia 1%
Disc. AE
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Nausea 1%
Disc. AE
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Vomiting 1%
Disc. AE
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Headache 2%
Disc. AE
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Dizziness 3%
Disc. AE
22.5 mg/kg 2 times / day multiple, oral
Studied dose
Dose: 22.5 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 22.5 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inducer
1087
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2E1
1060

P-gp
1741
CYP
303

P-gp
2052
CYP1A
59
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
P-gp
1932
 inconclusive
CYP1A
122
 no
CYP3A4
2633
 weak
yes (co-administration study)
Comment: coadministration with triazolam resulted in a 37% decrease in AUC and 23% decrease in Cmax of triazolam
Page: 21.0
CYP2E1
1146
 yes [Ki 450 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP
303
 no
P-gp
2052
 no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY34223
https://www.001chemical.com/chem/106308-44-5
3B Scientific (Wuhan) Corp
3B3-032294
http://www.3bsc.com/index/pro_info.php?id=53558
AA Blocks
AA0083RI
https://www.aablocks.com/goods/Goods/detail?id=AA0083RI
Aaron Chemicals
AR0084JA
http://www.aaronchem.com/106308-44-5
abcr GmbH
AB505794
http://www.abcr.com/shop/en/AB505794
AbMole Bioscience
M5943
http://www.abmole.com/search?q=M5943
Acadechem
ACDS-026251
http://www.acadechemical.com/product/100950
Achemtek
0104-006439
http://www.achemtek.com/106308-44-5
AHH Chemical co.,ltd
MT-27313
http://www.ahhchemical.com/product/MT-27313.html
AK Scientific, Inc. (AKSCI)
J10459
http://www.aksci.com/item_detail.php?cat=J10459
AK Scientific, Inc. (AKSCI)
Q503
http://www.aksci.com/item_detail.php?cat=Q503
Alfa Chemistry
AP106308445
https://reagents.alfa-chemistry.com/product/rufinamide-cas-106308-44-5-1178.html
Ambeed
A193932
https://www.ambeed.com/products/106308-44-5.html
Angel Pharmatech
AG100069
http://www.angelpharmatech.com/106308-44-5.html
Angene
AGN-PC-04XLIP
http://www.angenechemical.com/productshow/AGN-PC-04XLIP.html
ApexBio Technology
B2280
http://www.apexbt.com/rufinamide.html
Ark Pharm
AK00592772
http://www.arkpharminc.com/products/106308-44-5.html
Aromsyn
AS07135
http://www.aromsyn.com/product/AS07135.html
Aurora Fine Chemicals LLC
A13.142.788
http://online.aurorafinechemicals.com/info?ID=A13.142.788
Aurum Pharmatech LLC
W-5135
http://www.Aurumpharmatech.com/Product/ProductDetails/W_5135
AvaChem Scientific
6755
https://www.avachem.com/productSearch.asp?6755
BioChemPartner
BCP21828
http://www.biochempartner.com/106308-44-5-BCP21828
BioCrick
BCC5078
http://www.biocrick.com/Rufinamide-BCC5078.html
BioSynth
J-001568
https://www.biosynth.com/en/products/all-products/products/J-001568.html
BLD Pharm
BD150601
http://www.bldpharm.com/products/106308-44-5.html
Boerchem
BC224496
http://www.boerchem.com/?product_37826.html
Capot Chemical
14896
http://www.capotchem.com/en/14896.htm
Capot Chemical
PubChem14896
http://www.capotchem.com/en/14896.htm
Chem Scene
CS-1455
http://www.chemscene.com/106308-44-5.html
Chemenu
CM110361
http://www.chemenu.com/products/CM110361
ChemMol
30108593
http://www.chemmol.com/chemmol/30108593.html
ChemMol
44007210
http://www.chemmol.com/chemmol/44007210.html
ChemMol
49400040
http://www.chemmol.com/chemmol/49400040.html
ChemMol
51502959
http://www.chemmol.com/chemmol/51502959.html
ChemMol
97900688
http://www.chemmol.com/chemmol/97900688.html
Chemspace
CSSB00000694639
https://chem-space.com/CSSB00000694639
Clearsynth
CS-O-02240
https://www.clearsynth.com/en/CSO02240.html
Clearsynth
CS-T-42005
https://www.clearsynth.com/en/CST42005.html
CSNpharm
CSN11872
https://www.csnpharm.com/products/rufinamide.html
DC Chemicals
DC7272
http://www.dcchemicals.com/product_show-Rufinamide.html
Enamine
Z1541638521
https://www.enaminestore.com/catalog/Z1541638521
eNovation Chemicals
D546945
https://www.enovationchem.com/ProductDetails.asp?ProductID=D546945
Finetech
FT-0656828
http://www.finetechnology-ind.com/prod/detail/pub/106308-44-5.html
Finetech
FT-0674479
http://www.finetechnology-ind.com/prod/detail/pub/170939-95-4.html
Glentham Life Sciences
GP1695
http://www.glentham.com/products/product/GP1695/
Hairui
HR111623
http://www.hairuichem.com/en/product/106308-44-5.html
Hello Bio
HB1039
https://www.hellobio.com/rufinamide.html
iChemical
EBD35607
http://www.ichemical.com/chemicals/cas-106308-44-5
Lab Network
LN00236052
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00236052
mcule
MCULE-6872329028
https://mcule.com/MCULE-6872329028/
MedChem Express
HY-A0042
https://www.medchemexpress.com/rufinamide.html
Molcore
MC34223
https://www.molcore.com/product/106308-44-5
MuseChem
I000319
https://www.musechem.com/product/I000319.html
OChem
9340
http://www.ocheminc.com/index.php?act=psearch&pid=308R445
Selleck Chemicals
S1256
http://www.selleckchem.com/products/Rufinamide.html
Sigma-Aldrich
1606401_USP
https://www.sigmaaldrich.com/catalog/product/usp/1606401?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
PHR1625_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/phr1625?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
R8404_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/r8404?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech
S010594
http://www.sinfoobiotech.com/product/1013992
Smolecule
S542061
http://www.smolecule.com/products/s542061
Smolecule
S774580
https://www.smolecule.com/products/s774580
Synblock Inc
SB18904
http://www.synblock.com/product/106308-44-5.html
Synchem UG and Co KG
68220
http://www.synchem.de/chemical_Rufinamide.html
TCI (Tokyo Chemical Industry)
R0143
http://www.tcichemicals.com/eshop/en/us/commodity/R0143/index.html
THE BioTek
bt-280582
https://www.thebiotek.com/product/inhibitors/bt-280582
Tocris
3828
https://www.tocris.com/products/rufinamide_3828
VladaChem
VL278792-100MG
https://www.vladachem.com/product.php?products=106308-44-5
Yuhao Chemical
RT2381
http://www.chemyuhao.com/106308-44-5.html
PubMed

PubMed

TitleDatePubMed
Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview.
2011-04-01
Selected pharmacokinetic issues of the use of antiepileptic drugs and parenteral nutrition in critically ill patients.
2010-12-31
Ethyl 1-(2,6-difluoro-benz-yl)-1H-1,2,3-triazole-4-carboxyl-ate.
2010-12-15
"Epileptic encephalopathy" of infancy and childhood: electro-clinical pictures and recent understandings.
2010-12
New drugs for pediatric epilepsy.
2010-12
Post-treatment with voltage-gated Na(+) channel blocker attenuates kainic acid-induced apoptosis in rat primary hippocampal neurons.
2010-12
Expression, regulation and function of phosphofructo-kinase/fructose-biphosphatases (PFKFBs) in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia cells.
2010-11-23
Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience.
2010-11
Treating Lennox-Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide.
2010-10-05
Antiepileptic drug interactions - principles and clinical implications.
2010-09
Experience with rufinamide in a pediatric population: a single center's experience.
2010-09
Emerging drugs for partial onset seizures.
2010-09
Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study.
2010-09
New antiepileptic drugs: lacosamide, rufinamide, and vigabatrin.
2010-07
Update on anticonvulsant drugs.
2010-07
Rufinamide: a new antiepileptic drug treatment for Lennox-Gastaut syndrome.
2010-06
Severe constipation associated with the use of rufinamide (Banzel) in an adolescent.
2010-05
[Antiepileptic drugs in North America].
2010-05
Medical management of Lennox-Gastaut syndrome.
2010-05
Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs.
2010-04
Gateways to clinical trials.
2010-04
Rufinamide: a new antiepileptic medication for the treatment of seizures associated with lennox-gastaut syndrome.
2010-04
First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy.
2010-04
Gateways to clinical trials.
2010-03
Stability of extemporaneously prepared rufinamide oral suspensions.
2010-03
Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy.
2010-02-01
Supporting the recommended paediatric dosing regimen for rufinamide in Lennox-Gastaut syndrome using clinical trial simulation.
2010-02
New Drugs2010, PART 1.
2010-02
A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures.
2010-02
Lennox-Gastaut syndrome: An overview.
2010-01
Rufinamide: a novel broad-spectrum antiepileptic drug.
2010-01
Drug interactions involving the new second- and third-generation antiepileptic drugs.
2010-01
Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom.
2010-01
Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives.
2010-01
The possible antianxiety and mood-stabilizing effects of rufinamide.
2010
The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK.
2010
Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies.
2009-12
Gateways to clinical trials.
2009-11
Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial.
2009-08
Treatment of Lennox-Gastaut syndrome.
2009-07-08
Minimizing AED adverse effects: improving quality of life in the interictal state in epilepsy care.
2009-06
Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects.
2009-06
Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions.
2009-06
Antiepileptic drug monotherapy: the initial approach in epilepsy management.
2009-06
Adopting an orphan drug: rufinamide for Lennox-Gastaut syndrome.
2009-05-28
New drugs: Febuxostat, lacosamide, and rufinamide.
2009-05-16
Onset of action and seizure control in Lennox-Gaustaut syndrome: focus on rufinamide.
2009-04
Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide.
2009
Rufinamide: Further evaluation is needed in Lennox-Gastaut syndrome.
2008-08
Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions.
2008-03-02
Patents

Patents

08183269
2
EP 199262
1
US 4789680
1

Sample Use Guides

In Vivo Use Guide
Starting daily dose: 400-800 mg per day in two equally divided doses. Increase by 400-800 mg every other day until a maximum dose of 3200 mg per day, in two divided doses, is reached.
Route of Administration: Oral
In Vitro Use Guide
In vitro studies with human liver microsomes using con-centrations of rufinamide in the range of 10–300 µmol/L(2.4–72 µg/ml) found no significant inhibition of any ofeight major human CYP isozymes—CYP1A2, CYP2A6,CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, andCYP4A9/11.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:03:57 GMT 2025
Edited
by admin
on Mon Mar 31 18:03:57 GMT 2025
Record UNII
WFW942PR79
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RUFINAMIDE
DASH   EMA EPAR   INN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
BANZEL
Preferred Name English
1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
Systematic Name English
1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE, 1-((2,6-DIFLUOROPHENYL)METHYL)-
Systematic Name English
RUFINAMIDE [ORANGE BOOK]
Common Name English
RUFINAMIDE [JAN]
Common Name English
INOVELON
Brand Name English
RUFINAMIDE [MART.]
Common Name English
RUF 331
Code English
RUFINAMIDE [EMA EPAR]
Common Name English
CGP 33101
Code English
E-2080
Code English
Rufinamide [WHO-DD]
Common Name English
CGP-33101
Code English
RUFINAMIDE [VANDF]
Common Name English
RUFINAMIDE [USP MONOGRAPH]
Common Name English
RUF-331
Code English
60231/4
Code English
RUFINAMIDE [MI]
Common Name English
E2080
Code English
RUFINAMIDE [USP-RS]
Common Name English
RUFINAMIDE [USAN]
Common Name English
rufinamide [INN]
Common Name English
Classification Tree Code System Code
WHO-ATC N03AF03
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
NCI_THESAURUS C264
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
WHO-VATC QN03AF03
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
LIVERTOX NBK548457
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
EU-Orphan Drug EU/3/04/240
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
EMA ASSESSMENT REPORTS INOVELON (AUTHORIZED: EPILEPSY)
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
FDA ORPHAN DRUG 193504
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
Code System Code Type Description
MESH
C079703
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
INN
7387
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
WIKIPEDIA
RUFINAMIDE
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
CAS
106308-44-5
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
FDA UNII
WFW942PR79
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
PUBCHEM
129228
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
IUPHAR
7470
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
EVMPD
SUB10403MIG
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
DAILYMED
WFW942PR79
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201754
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
RXCUI
69036
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY RxNorm
LACTMED
Rufinamide
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
SMS_ID
100000089186
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
MERCK INDEX
m9696
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY Merck Index
RS_ITEM_NUM
1606401
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
NCI_THESAURUS
C75167
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
USAN
SS-30
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
DRUG BANK
DB06201
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
EPA CompTox
DTXSID1046506
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
DRUG CENTRAL
3534
Created by admin on Mon Mar 31 18:03:57 GMT 2025 , Edited by admin on Mon Mar 31 18:03:57 GMT 2025
PRIMARY
Related Record Type Details
CYTOCHROME P450 2E1
METABOLIC ENZYME -> INHIBITOR
Ki
Structure of RUFINAMIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Structure of RUFINAMIDE
EXCRETED UNCHANGED
FECAL; URINE
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INDUCER
WEAK
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
SODIUM CHANNEL PROTEIN TYPE 1 SUBUNIT ALPHA
TARGET -> INHIBITOR
Shifts hNav1.1 opening to more depolarized voltages without further alterations in the gating properties of hNav1.1, hNav1.2, hNav1.3, and hNav1.6;
Related Record Type Details
Structure of CGP-47292
METABOLITE -> PARENT
MAJOR
PLASMA
Structure of .BETA.-D-GLUCOPYRANURONIC ACID, 1-(1-((2,6-DIFLUOROPHENYL)METHYL)-1H-1,2,3-TRIAZOLE-4-CARBOXYLATE)
METABOLITE -> PARENT
MINOR
URINE
Related Record Type Details
Structure of DESFLUORORUFINAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of RUFINAMIDE-5-CARBOXAMIDE
IMPURITY -> PARENT
Structure of CGP-47292 METHYL ESTER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of RUFINAMIDE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966